Literature DB >> 10632000

Three decades of corneal transplantation: indications and patient characteristics.

A Maeno1, J Naor, H M Lee, W S Hunter, D S Rootman.   

Abstract

PURPOSE: To review the indications and patient characteristics for penetrating keratoplasty (PKP).
METHODS: Retrospective review of records at the Pathology Service, Department of Ophthalmology, University of Toronto from 1964 to 1997.
RESULTS: The 6,222 records were reviewed. The leading indications for PKP were regraft, keratoconus (KC), pseudophakic bullous keratopathy (PBK), Fuchs' dystrophy, viral infections, and trauma, in that order. During the second half of the 1980s, PBK replaced KC as the leading indication for transplantation. The average age of patients increased from 49 (+/-19) years during the second half of the 1960s to 63 (+/-20) years at the first half of the 1990s. Gender differences (M/F ratio) were significant for KC, viral keratopathy, trauma, PBK, aphakic bullous keratopathy (ABK), edema of unspecified etiology, interstitial keratitis, rheumatoid arthritis, and Fuchs' dystrophy. Diagnostic category differences between all patients for PKPs and regrafts were significant for autoimmune keratolysis, congenital opacities, PBK, ABK, edema of unspecified etiology, scarring, Fuchs' dystrophy, and KC.
CONCLUSION: Indications are in accordance with the literature with the exception of regraft, which was higher. An increase in the average age of patients corresponded with the PBK epidemic. The high male-to-female ratio among patients with KC was different from that previously reported for the prevalence of this condition. Sex distribution among patients with PBK and ABK showed a female predominance. Differences in the underlying disease distributions between regrafted patients and the rest of the series coincide with prognostic classifications for PKP.

Entities:  

Mesh:

Year:  2000        PMID: 10632000     DOI: 10.1097/00003226-200001000-00002

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  35 in total

1.  Penetrating keratoplasty: indications over a 10 year period.

Authors:  N Al-Yousuf; I Mavrikakis; E Mavrikakis; S M Daya
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

2.  [The extracellular matrix structure in keratoconus].

Authors:  O Stachs; A Bochert; T Gerber; D Koczan; H J Thiessen; R F Guthoff
Journal:  Ophthalmologe       Date:  2004-04       Impact factor: 1.059

3.  Indications for penetrating keratoplasty in East China, 1994-2003.

Authors:  Chaoran Zhang; Jianjiang Xu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-10-20       Impact factor: 3.117

Review 4.  Surgical alternatives to penetrating keratoplasty II: endothelial keratoplasty.

Authors:  Kenneth M Goins
Journal:  Int Ophthalmol       Date:  2008-06       Impact factor: 2.031

5.  Repeat penetrating keratoplasty: indications, graft survival, and visual outcome.

Authors:  H Al-Mezaine; M D Wagoner
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

6.  Fuchs' corneal dystrophy.

Authors:  Allen O Eghrari; John D Gottsch
Journal:  Expert Rev Ophthalmol       Date:  2010-04

7.  Cornea procurement from very old donors: post organ culture cornea outcome and recipient graft outcome.

Authors:  P Gain; G Thuret; C Chiquet; P Rizzi; J L Pugniet; S Acquart; J J Colpart; J C Le Petit; J Maugery
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

8.  Intrastromal corneal ring implants for corneal thinning disorders: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2009-04-01

9.  Collagen cross-linking using riboflavin and ultraviolet-a for corneal thinning disorders: an evidence-based analysis.

Authors:  G Pron; L Ieraci; K Kaulback
Journal:  Ont Health Technol Assess Ser       Date:  2011-11-01

10.  Influence of sex on gene expression in human corneal epithelial cells.

Authors:  Tomo Suzuki; Stephen M Richards; Shaohui Liu; Roderick V Jensen; David A Sullivan
Journal:  Mol Vis       Date:  2009-12-03       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.